SCHEMBL2632977

SCHEMBL2632977

CBc1cc2c(C)nc(NCCN3CCOCC3)nc2n(CC)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.50
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGD P15428 3/20 0.50
GAA P10253 2/20 0.50
HSD17B10 Q99714 2/20 0.50
HTT P42858 2/20 0.50
GLA P06280 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
TLR9 Q9NR96 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPK8 P45983 1/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
POLB P06746 2/20 0.39
PIK3CA P42336 5/20 0.39
MTOR P42345 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL188523 0.88 MAPK1 (0.66) MAPK1KDM4EALDH1A1HPGDGAA
SCHEMBL188644 0.83 ALDH1A1 (0.64) MAPK1KDM4EALDH1A1HPGDGAA
SCHEMBL14301327 0.76 ALDH1A1 (0.56) MAPK1KDM4EALDH1A1HPGDGAA
SCHEMBL12458504 0.75 RXFP1 (0.54) MAPK1KDM4EALDH1A1HPGDGAA
SCHEMBL188695 0.68 ALDH1A1 (1.00) MAPK1KDM4EALDH1A1HPGDGAA
SCHEMBL188921 0.67 MAPK1 (0.58) MAPK1KDM4EALDH1A1HPGDGAA
SCHEMBL26723719 0.67 KMT2A (0.48) MAPK1KDM4EALDH1A1HPGDGAA
SCHEMBL1899279 0.67 ALDH1A1 (0.74) MAPK1KDM4EALDH1A1HPGDGAA
SCHEMBL20614374 0.67 ALDH1A1 (0.55) MAPK1KDM4EALDH1A1HPGDGAA
SCHEMBL188562 0.67 ALDH1A1 (0.70) MAPK1KDM4EALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2056829-B9 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS INC (US) 2012-09-26 EP disclosed
EP-2056829-B1 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS INC (US) 2012-01-04 EP disclosed